Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Raymond Taeyong Chung, M.D.

Co-Author

This page shows the publications co-authored by Raymond Chung and Tracey Simon.
Connection Strength

7.355
  1. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol. 2018 05 15; 259:198-204.
    View in: PubMed
    Score: 0.781
  2. Reply. Hepatology. 2016 06; 63(6):2066-7.
    View in: PubMed
    Score: 0.658
  3. The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Antivir Ther. 2016; 21(3):185-94.
    View in: PubMed
    Score: 0.652
  4. The new hepatitis C virus bottleneck: Can delaying therapy be justified? Hepatology. 2015 Sep; 62(3):666-7.
    View in: PubMed
    Score: 0.642
  5. Reply to: "Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis". J Hepatol. 2015 Jul; 63(1):279.
    View in: PubMed
    Score: 0.625
  6. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015 Jan; 62(1):18-23.
    View in: PubMed
    Score: 0.602
  7. Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Hepatol Commun. 2021 01; 5(1):133-143.
    View in: PubMed
    Score: 0.232
  8. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med. 2020 03 12; 382(11):1018-1028.
    View in: PubMed
    Score: 0.222
  9. Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. J Hepatol. 2020 06; 72(6):1062-1069.
    View in: PubMed
    Score: 0.219
  10. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Ann Intern Med. 2019 09 03; 171(5):318-327.
    View in: PubMed
    Score: 0.213
  11. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019 12; 17(13):2776-2784.e4.
    View in: PubMed
    Score: 0.209
  12. The immunity-related GTPase M rs13361189 variant does not increase the risk for prevalent or incident steatosis; results from the Framingham Heart Study. Liver Int. 2019 06; 39(6):1022-1026.
    View in: PubMed
    Score: 0.206
  13. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol. 2018 12 01; 4(12):1683-1690.
    View in: PubMed
    Score: 0.203
  14. IRGM Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease. Inflamm Bowel Dis. 2018 09 15; 24(10):2247-2257.
    View in: PubMed
    Score: 0.200
  15. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018 Nov 01; 270:245-252.
    View in: PubMed
    Score: 0.196
  16. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology. 2018 05; 67(5):1797-1806.
    View in: PubMed
    Score: 0.193
  17. Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. Obesity (Silver Spring). 2017 08; 25(8):1313-1316.
    View in: PubMed
    Score: 0.185
  18. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis. Metabolism. 2017 10; 75:1-5.
    View in: PubMed
    Score: 0.184
  19. MELD-Na score predicts incident major cardiovascular events, in patients with nonalcoholic fatty liver disease (NAFLD). Hepatol Commun. 2017 Jul; 1(5):429-438.
    View in: PubMed
    Score: 0.182
  20. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci. 2016 12; 61(12):3425-3435.
    View in: PubMed
    Score: 0.175
  21. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology. 2016 07; 64(1):47-57.
    View in: PubMed
    Score: 0.168
  22. Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical Outcomes. Dig Dis Sci. 2015 Jul; 60(7):2190-5.
    View in: PubMed
    Score: 0.156
  23. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2021 Sep 02.
    View in: PubMed
    Score: 0.061
  24. Association Between Liver Fat and Bone Density is Confounded by General and Visceral Adiposity in a Community-Based Cohort. Obesity (Silver Spring). 2021 03; 29(3):595-600.
    View in: PubMed
    Score: 0.059
  25. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology. 2018 06; 67(6):2244-2253.
    View in: PubMed
    Score: 0.049
  26. Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. BMC Infect Dis. 2015 Nov 11; 15:510.
    View in: PubMed
    Score: 0.041
  27. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. Hepatology. 2015 Aug; 62(2):365-74.
    View in: PubMed
    Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.